Gilead pulls plug on magrolimab in AML

8 February 2024

Gilead Sciences (Nasdaq: GILD) announced it has discontinued the Phase III ENHANCE-3 study of magrolimab in acute myeloid leukemia (AML), with the news sending the US biotech major’s shares down more than 4% to $74.42 by close on trading on Wednesday

Gilead, which already warned last year that it would be stopping the study last year, also revealed that the US Food and Drug Administration (FDA) has placed all magrolimab studies in myelodysplastic syndromes (MDS) and AML, including related expanded access programs, on full clinical hold.

The candidate was acquired via the $4.9 billion buyout of Forty-Seven, which took place in 2020, as part of a push to diversify the pipeline and become less dependent on anti-virals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK